| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 4th, 2005 | 20 | No |
Popular Name: CYCLOHEXIMIDE CYCLOHEXIMIDE
2,6-piperidinedione, 4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-
3-[2-(3,5-Dimethyl-2-Oxocyclohexyl)-2-Hydroxyethyl)-Glutarimide [66-81-9]; (Cycloheximide)
3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide
4-[(2R)-2-[(1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione
4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]piperidine-2,6-dione
66-81-9; C06685; Cycloheximide
66-81-9; Cicloheximide (INN); Cycloheximide (USAN); D03625
66-81-9; Cycloheximide; Prestwick_976
Cicloheximide (INN); Cycloheximide (USAN)
Cycloheximide, Antibiotic for Culture Media Use Only
Cycloheximide, Streptomyces griseus
GNF-Pf-5118; NSC-171; TCMDC-125838
z3-[2-(3,5-DIMETHYL-2-OXOCYCLOHEXYL)-2-HYDROXYETHYL]-GLUTARIMIDE; [66-81-9]
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 0.76 | 3.22 | -17 | 2 | 5 | 0 | 83 | 281.352 | 3 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| Molecular_Solubility | 2.497 | Bitter DB |
| Mp [°C] | 107 - 114 | Acros Organics |
| M.P | 111-116 °C | Indofine |
| MP | 112-118° | Oakwood Chemical |
| UniProt Database Links | 1A110_ARATH; 1A111_ARATH; 1A112_ARATH; 1A12_ARATH; 1A14_ARATH; 1A15_ARATH; 1A16_ARATH; 1A17_ARATH; 1A18_ARATH; 1A19_ARATH; AB1B_ARATH; AB31G_ARATH; AB32G_ARATH; AB33G_ARATH; AB35G_ARATH; AB36G_ARATH; AB37G_ARATH; AB40G_ARATH; ABC2_SCHPO; ABC4_SCHPO; ARG7_ | ChEBI |
| biological_use | Active against Saccharomyces pastorianus | IBScreen Bioactives |
| biological_use | Antifungal agent | IBScreen Bioactives IBScreen Bioactives |
| therap | antipsoriatic, protein synthesis inhibitor | MicroSource Spectrum |
| Notes | Assay (by LC) 95+%Inhibitor of protein synthesis | Apollo Scientific Bioactives |
| Patent Database Links | EP1533382; EP1574499; GB2035085; GB2321455; US2001006962; US2003153544; US2004063677; US2007244165; US2008249113; WO2005085196; WO2007089548; WO2008117079 | ChEBI |
| H phrase | H411: Toxic to aquatic life with long lasting effects | Acros Organics |
| H phrase | H411: Toxic to aquatic life with long lasting effects; H300: Fatal if swallowed; H341: Suspected of causing genetic defects; H360D: May damage the unborn child | Acros Organics |
| mechanism | Inhibitor of ribosome functions 1 1580 | IBScreen Bioactives |
| P phrase | P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician | Acros Organics |
| P phrase | P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician; P281: Use personal protective equipment as required; P201: Obtain special instructions before use; P308 + P313: IF exposed or concerned: Get medical advice/attention; P273: A | Acros Organics |
| Therapy | protein synthesis inhibitor | SMDC Iconix |
| R phrase | R61: May cause harm to the unborn child. | Acros Organics |
| R phrase | R61: May cause harm to the unborn child.; R28: Very toxic if swallowed.; R51/53: Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.; R68: Possible risks of irreversible effects. | Acros Organics |
| S phrase | S53: Avoid exposure - obtain special instructions before use. | Acros Organics |
| S phrase | S53: Avoid exposure - obtain special instructions before use.; S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).; S61: Avoid release to the environment. Refer to special instructions / safety | Acros Organics |
| Hazard | T+: Very toxic | Acros Organics |
| Hazard | T+: Very toxic; N: Dangerous for the environment | Acros Organics |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| FKB1A-1-E | FK506-binding Protein 1A (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3600 | 0.38 | Binding ≤ 10μM |
| Z50347-2-O | Saccharomyces Cerevisiae (cluster #2 Of 3), Other | Other | 88 | 0.49 | Functional ≤ 10μM |
| Z50425-4-O | Plasmodium Falciparum (cluster #4 Of 22), Other | Other | 200 | 0.47 | Functional ≤ 10μM |
| Z50466-5-O | Trypanosoma Cruzi (cluster #5 Of 8), Other | Other | 400 | 0.45 | Functional ≤ 10μM |
| Z50587-4-O | Homo Sapiens (cluster #4 Of 9), Other | Other | 930 | 0.42 | Functional ≤ 10μM |
| Z50592-3-O | Oryctolagus Cuniculus (cluster #3 Of 8), Other | Other | 5000 | 0.37 | Functional ≤ 10μM |
| Z80026-2-O | AGS (Gastric Adenocarcinoma Cells) (cluster #2 Of 2), Other | Other | 3600 | 0.38 | Functional ≤ 10μM |
| Z80224-6-O | MCF7 (Breast Carcinoma Cells) (cluster #6 Of 14), Other | Other | 1500 | 0.41 | Functional ≤ 10μM |
| Z80390-3-O | PC-3 (Prostate Carcinoma Cells) (cluster #3 Of 10), Other | Other | 3500 | 0.38 | Functional ≤ 10μM |
| Z80485-2-O | SK-MEL-28 (Melanoma Cells) (cluster #2 Of 6), Other | Other | 1000 | 0.42 | Functional ≤ 10μM |
| Z80490-1-O | SK-MES-1 (cluster #1 Of 4), Other | Other | 2700 | 0.39 | Functional ≤ 10μM |
| Z80583-3-O | Vero (Kidney Cells) (cluster #3 Of 7), Other | Other | 530 | 0.44 | Functional ≤ 10μM |
| Z80653-1-O | 9L (Glioma Cells) (cluster #1 Of 2), Other | Other | 200 | 0.47 | Functional ≤ 10μM |
| Z80874-4-O | CEM (T-cell Leukemia) (cluster #4 Of 7), Other | Other | 80 | 0.50 | Functional ≤ 10μM |
| Z81020-4-O | HepG2 (Hepatoblastoma Cells) (cluster #4 Of 8), Other | Other | 2500 | 0.39 | Functional ≤ 10μM |
| Z81072-7-O | Jurkat (Acute Leukemic T-cells) (cluster #7 Of 10), Other | Other | 930 | 0.42 | Functional ≤ 10μM |
| Z81170-3-O | LNCaP (Prostate Carcinoma) (cluster #3 Of 5), Other | Other | 1200 | 0.41 | Functional ≤ 10μM |
| Z81247-6-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #6 Of 9), Other | Other | 533 | 0.44 | Functional ≤ 10μM |
| Z81252-4-O | MDA-MB-231 (Breast Adenocarcinoma Cells) (cluster #4 Of 11), Other | Other | 1200 | 0.41 | Functional ≤ 10μM |
| Z80005-2-O | 3T3 (Fibroblast Cells) (cluster #2 Of 2), Other | Other | 912 | 0.42 | ADME/T ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| FKB1A_HUMAN | P62942 | FK506-binding Protein 1A, Human | 3400 | 0.38 | Binding ≤ 10μM |
| Z80653 | Z80653 | 9L (Glioma Cells) | 200 | 0.47 | Functional ≤ 10μM |
| Z80026 | Z80026 | AGS (Gastric Adenocarcinoma Cells) | 3600 | 0.38 | Functional ≤ 10μM |
| Z80874 | Z80874 | CEM (T-cell Leukemia) | 120 | 0.48 | Functional ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 2880.1 | 0.39 | Functional ≤ 10μM |
| Z81020 | Z81020 | HepG2 (Hepatoblastoma Cells) | 2500 | 0.39 | Functional ≤ 10μM |
| Z50587 | Z50587 | Homo Sapiens | 930 | 0.42 | Functional ≤ 10μM |
| Z81072 | Z81072 | Jurkat (Acute Leukemic T-cells) | 930 | 0.42 | Functional ≤ 10μM |
| Z81170 | Z81170 | LNCaP (Prostate Carcinoma) | 1200 | 0.41 | Functional ≤ 10μM |
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 1500 | 0.41 | Functional ≤ 10μM |
| Z81252 | Z81252 | MDA-MB-231 (Breast Adenocarcinoma Cells) | 1200 | 0.41 | Functional ≤ 10μM |
| Z50592 | Z50592 | Oryctolagus Cuniculus | 5000 | 0.37 | Functional ≤ 10μM |
| Z80390 | Z80390 | PC-3 (Prostate Carcinoma Cells) | 3500 | 0.38 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 100 | 0.49 | Functional ≤ 10μM |
| Z50347 | Z50347 | Saccharomyces Cerevisiae | 227.3 | 0.47 | Functional ≤ 10μM |
| Z80485 | Z80485 | SK-MEL-28 (Melanoma Cells) | 1000 | 0.42 | Functional ≤ 10μM |
| Z80490 | Z80490 | SK-MES-1 | 2700 | 0.39 | Functional ≤ 10μM |
| Z50466 | Z50466 | Trypanosoma Cruzi | 400 | 0.45 | Functional ≤ 10μM |
| Z80583 | Z80583 | Vero (Kidney Cells) | 1200 | 0.41 | Functional ≤ 10μM |
| Z80005 | Z80005 | 3T3 (Fibroblast Cells) | 260 | 0.46 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| TGF-beta receptor signaling activates SMADs | |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | |
| TGFBR1 KD Mutants in Cancer | |
| TGFBR1 LBD Mutants in Cancer | |
| TGFBR2 Kinase Domain Mutants in Cancer |
